These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32000577)

  • 1. Pharmaceutical Price and Spending Controls in France: Lessons for the United States.
    Rodwin MA
    Int J Health Serv; 2020 Apr; 50(2):156-165. PubMed ID: 32000577
    [No Abstract]   [Full Text] [Related]  

  • 2. Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States.
    Rodwin MA
    Int J Health Serv; 2021 Jul; 51(3):379-391. PubMed ID: 33686883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicine versus the Medicare purse. Paying the price for prescription drugs.
    Kole LA
    JAAPA; 2000 Mar; 13(3):6, 9. PubMed ID: 11503404
    [No Abstract]   [Full Text] [Related]  

  • 4. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New strategies to curb specialty drug costs.
    Goozner M
    Mod Healthc; 2014 Oct; 44(41):25. PubMed ID: 25509661
    [No Abstract]   [Full Text] [Related]  

  • 7. Health care cost containment strategies used in four other high-income countries hold lessons for the United States.
    Stabile M; Thomson S; Allin S; Boyle S; Busse R; Chevreul K; Marchildon G; Mossialos E
    Health Aff (Millwood); 2013 Apr; 32(4):643-52. PubMed ID: 23569043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
    Vogel RJ
    Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicaid preferred drug lists: cost containment and side effects.
    Headen AE
    Pharmacoeconomics; 2006; 24 Suppl 3():1-3. PubMed ID: 17266384
    [No Abstract]   [Full Text] [Related]  

  • 11. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
    Gross DJ; Ratner J; Perez J; Glavin SL
    Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 13. Prescription drug spending: contribution to health care spending and cost containment strategies.
    Rivers PA; Hall NG; Frimpong J
    J Health Care Finance; 2006; 32(3):8-19. PubMed ID: 18975728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
    Maniadakis N; Kourlaba G; Shen J; Holtorf A
    BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kaura S
    Health Aff (Millwood); 2016 Sep; 35(9):1588-94. PubMed ID: 27605637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of pharmacoeconomics in prescribing research. Part 1: costs--moving beyond the acquisition price for drugs.
    Robertson J; Lang D; Hill S
    J Clin Pharm Ther; 2003 Feb; 28(1):73-9. PubMed ID: 12605622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Payers struggle to ensure high level of adherence to costly specialty drugs.
    Sipkoff M
    Manag Care; 2008 Jul; 17(7):24-6, 29, 31. PubMed ID: 18757021
    [No Abstract]   [Full Text] [Related]  

  • 19. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European countries seek to cut drug costs.
    Burki T
    Lancet Oncol; 2010 Jul; 11(7):614-5. PubMed ID: 20629204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.